Randomized Clinical Trial of Middle Meningeal Artery Embolization for Patients with Refractory Chronic Subdural Hematoma

Randomized Clinical Trial of Middle Meningeal Artery Embolization for Patients with Refractory Chronic Subdural Hematoma - COMPLEMENT study: ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000055317

Enrollment

600

Registered

2024-12-01

Start date

2024-12-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Subdural Hematoma

Interventions

Conventional treatment with middle meningeal artery embolization Conventional treatment alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age >=18 2) pre-mRS 0-3 3) Hematoma thickness >=10mm 4) Having at least one risk factor Risk factor: Age >=75, Antithrombotic therapy, DM, Bilateral hematoma, Markwalder grading score >3, Preoperative volume >=130ml, Preoperative midline shift >=8mm, CT appearance (Homogeneous, laminar or separated)

Exclusion criteria

Exclusion criteria: 1) Cr >=1.8 2) Plt <50,000, PT-INR >2 3) Life expectancy <6 months

Design outcomes

Primary

Measure	Time frame
Recurrence of chronic subdural hematoma within 6 months after randomization	—

Countries

Japan

Contacts

Public ContactKazutaka Uchida

Hyogo Medical University Department of Neurosurgery

kuchida@hyo-med.ac.jp0798-45-6455

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026